Abstract
Low-grade ovarian cancers comprise <10% of all ovarian cancers and are relatively chemo-resistant compared to high-grade subtypes. While studies have shown that a delay in adjuvant chemotherapy for high-grade serous ovarian cancer is associated with worse survival, no such relationship has been studied in low-grade ovarian cancers. The objective of this study is to determine the association between timing of adjuvant therapy initiation and survival outcomes in patients with low-grade ovarian, fallopian tube, and primary peritoneal carcinoma.
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call